Prot #2215-CL-0101: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date9/23/13 → 9/23/16

Funding

  • Astellas Pharma Global Development, Inc. (Prot #2215-CL-0101)